Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy
- 23 February 2023
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (3) , 750-752
Abstract
Acute myeloid leukemia (AML) is a life-threatening disease that requires urgent treatment. The standard of care for initial treatment is induction chemotherapy, most commonly with a backbone includ...Keywords
Funding Information
- NIH TL1 (TR001858)
This publication has 7 references indexed in Scilit:
- Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyLeukemia Research, 2022
- Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-inductionHaematologica, 2019
- Day 14 bone marrow examination in the management of acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘Day 14’ without further therapy in acute myeloid leukemiaLeukemia & Lymphoma, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003